It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Over the past decade, lung cancer has emerged as a shining example of how precision medicine can dramatically improve patient outcomes. Up […] Read more
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […] Read more
By Denis Moro-Sibilot, MD, MSc Posted: April 16, 2020 Dr. Denis Moro-Sibilot EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of the […] Read more
By Jill Feldman, EGFR Resisters Co-Founder Posted: December 11, 2019 Jill Feldman I was so glad to see the article by Dr. Amy Moore on PDX models in the October […] Read more
By Si-Yang Liu, MD, and Yi-Long Wu, MD Posted: November 12, 2019 Dr. Si-Yang Liu Dr. Yi-Long Wu In the twentieth century, adjuvant chemotherapy became the standard of care for […] Read more